{"text": "findings the general court recognizes that the side effects and risks of marijuana use on the human body have advanced to a point that requires the department of health and human services to update agency rules on packaging and labeling requirements for marijuana products dispensed in alternative treatment centers no detailed side effects or risks of use exist on current warning labels use of cannabis for therapeutic purposes rules amend rsa iii a to read as follows labeling standards a labels shall include a statement that the product has not been analyzed or approved by the fda is not certified to be free of contaminants that there is limited detailed information on the side effects of using the product and that there may be serious associated health risks b labels shall also state do not drive or operate heavy machinery when under the influence of this product keep this product away from children and c labels shall include side effects and use risks published by centers for disease control and prevention national institute on drug abuse the national academy of sciences and the american academy of family physicians they shall include but not be limited to psychosis and schizophrenia depression anxiety suicide increased blood pressure increased respiratory rates cardiac arrhythmia heart failure worsening of glaucoma cognitive impairment addiction allergic reactions accidental poisoning and coma in children preterm births to pregnant women and impacts on fetal brain development new paragraph use of cannabis for therapeutic purposes duties amend rsa by inserting after paragraph xi the following new paragraph prepare in conjunction with the bureau of alcohol and drug services and the division of public health services a brochure and a poster which provides information relative to the known side effects and risks of marijuana use which shall be posted in a conspicuous location and available to the public in all therapeutic cannabis dispensary locations pursuant to rsa", "status": 2, "party": 3}